Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option

The release as fetched from its publisher. biogen.com ↗